of afatinib in combination with docetaxel in patients with advanced solid tumors, known to express EGFR/HER2, who had progressed following prior standard therapies. The study defined the MTD of ...

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important ...

Drugs that target the EGFR protein and block its activity include: afatinib (Gilotrif) dacomitinib (Vizimpro) erlotinib (Tarceva) gefitinib (Iressa) osimertinib (Tagrisso) The most effective ...

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.

afatinib and dacotinib; and third-generation EGFR-TKI, osimertinib, that inhibits both EGFR-sensitive mutations and resistant mutation EGFR T790M. ALK inhibitors included first-generation ...